유틸렉스

263050KOSDAQ

50.0 / 100

Reference Date: 2026-09-08

Financial Score18.5 / 40

News Sentiment12.5 / 25

Momentum12.0 / 20

Disclosure7.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Roughly flat over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Utillex is a biotech company established in 2015, focusing on R&D of immunotherapies such as CAR-T and antibody-based treatments. Its key pipeline, EU307, is a 4th-generation armored CAR-T therapy targeting GPC3 in solid tumors, while EU103 converts M2 macrophages to M1 to enhance immune responses, both currently in Phase I clinical trials. The company also operates IT services and research-related business.

Number of Employees

119people

Average Salary

55.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

2.24Industry Average 1.201.0Point

1.9x industry avg (risky)

ROE

-88.55Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

21.94Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲3572.1% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲19.8% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -60.4% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (25%)

Current 959Won52-week high 1,74552-week low 683

1-month return3.0Point

1m 0% (flat)

Volume trend6.0Point

Volume surge

Detailed Disclosure

10 totalPositive 0Neutral 9Negative 1

Neutral[기재정정]대표이사변경2026-08-31
Neutral대표이사변경2026-08-28
Neutral임시주주총회결과2026-08-28
Neutral독립이사의선임ㆍ해임또는중도퇴임에관한신고2026-08-28
Negative소송등의판결ㆍ결정2026-08-19